OX2 Cancer Therapy
News and Updates
Featured Stories
All Stories
OX2 Reaches Recommended Phase 2 Dose Milestone in Pediatric Brain Tumor Trial
OX2 Therapeutics has reached RP2D in its ongoing clinical trial evaluating ARL200 + GBM6-AD Vaccine in pediatric patients with newly diagnosed Diffuse Midline Glioma and recurrent High-Grade Glioma.
Vaccine Trial Launched to Fight Pediatric Brain Cancer
University of Minnesota researchers have launched a promising vaccine trial targeting childhood brain cancer, offering hope to improve survival and quality of life for young patients.
New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials
OX2 Therapeutics has begun a Phase I clinical trial for a first-of-its-kind immunotherapy targeting aggressive brain tumors, aiming to boost the immune system and improve outcomes for patients.
FDA Grants IND Approval to OX2 Therapeutics to Initiate Phase I Clinical Trial of Its Peptide Checkpoint Modulator for Patients with CNS Tumors
OX2 Therapeutics has received clearance from the U.S. Food and Drug Administration to launch a phase 1 clinical trial with its new combination therapy for treatment of recurrent high grade brain tumors for which no curative therapy is available.